Several studies illuminate an association of the fibrinolytic marker, Plasminogen Activator Inhibitor 1 (PAI-1), in the progression of NAFLD and CVD [32]. Here, SERPINE1 is linked to metabolic dysfunction-associated steatotic liver disease.